Oncolytic viruses (OVs) provide novel and promising therapeutic options for patients with
cancers resistant to traditional therapies. Natural or genetically modified OVs are …

Viral vectors have been used for a broad spectrum of gene therapy for both acute and
chronic diseases. In the context of cancer gene therapy, viral vectors expressing anti-tumor …

Therapeutic cancer vaccines, an exciting development in cancer immunotherapy, share the
goal of creating and amplifying tumor-specific T-cell responses, but significant obstacles still …

To effectively build on the recent successes of immune checkpoint blockade, adoptive T cell
therapy and cancer vaccines, it is critical to rationally design combination strategies that will …

Recent clinical data have emphatically shown the capacity of our immune systems to
eradicate even advanced cancers. Although oncolytic viruses (OVs) were originally …

During the past decades, anticancer immunotherapy has evolved from a promising
therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now …

The recent successes of tumor immunotherapy approaches, such as immune checkpoint
blockade (ICB) and chimeric antigen receptor T cell (CAR-T) therapy, have revolutionized …

Background Cancer surgery is necessary and life-saving. However, the majority of patients
develop postoperative recurrence and metastasis, which are the main causes of cancer …

Since the discovery in 1796 by Edward Jenner of vaccinia virus as a way to prevent and
finally eradicate smallpox, the concept of using a virus to fight another virus has evolved into …

Highlights•Oncolytic viruses (OVs) can modulate tumour microenvironment (TME) towards
less immunosuppressive phenotype and induce anti-cancer immunity.•OVs can be used as …